Sales Already Growing As Vascepa Secures Cardio Approval
Fish Oil Derivative Seen As Biggest Advance In Decades
Executive Summary
Company forecasts 2020 sales as high as $700m after regulator grants broad label.
You may also be interested in...
Dr Reddy’s And Hikma Win Big On US Vascepa Patents
In a surprise to the market, Dr Reddy’s and Hikma have prevailed in challenging six method-of-use patents shielding Amarin’s Vascepa in the US, opening the door for a potential at-risk launch that would likely be challenged by the originator.
AstraZeneca's Dobber On Ramping In Renal, Expanding In CV And Business Development
Biopharmaceuticals President Ruud Dobber talked to Scrip about the launches of Lokelma and roxadustat in kidney disease, building with a high bar in cardiovascular disease and expanding in cell and gene therapy.
J.P. Morgan 2020: What To Watch For At The Industry’s Biggest Meeting
The J.P. Morgan Healthcare conference is being held a week later than usual, which only makes us more ready to hear what the industry's leaders have in store. Here's a preview of potential hot topics.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports